DK3820856T3 - C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner - Google Patents

C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner Download PDF

Info

Publication number
DK3820856T3
DK3820856T3 DK19769220.5T DK19769220T DK3820856T3 DK 3820856 T3 DK3820856 T3 DK 3820856T3 DK 19769220 T DK19769220 T DK 19769220T DK 3820856 T3 DK3820856 T3 DK 3820856T3
Authority
DK
Denmark
Prior art keywords
urinary tract
tract infections
treat urinary
mannoside compounds
mannoside
Prior art date
Application number
DK19769220.5T
Other languages
English (en)
Inventor
Michael Joseph Bishop
Vincent J Colandrea
Yuehu Li
Eugene L Stewart
Iulia Strambeanu
Katherine Louisa Widdowson
James Walter Janetka
Laurel Kathryn Mcgrane
Original Assignee
Glaxosmithkline Ip Dev Ltd
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Fimbrion Therapeutics Inc filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3820856T3 publication Critical patent/DK3820856T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C07D301/02—Synthesis of the oxirane ring
    • C07D301/03—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
    • C07D301/04—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen
    • C07D301/08—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase
    • C07D301/10—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase with catalysts containing silver or gold
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK19769220.5T 2018-07-10 2019-07-08 C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner DK3820856T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695993P 2018-07-10 2018-07-10
US201862755588P 2018-11-05 2018-11-05
PCT/IB2019/055806 WO2020012336A1 (en) 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections

Publications (1)

Publication Number Publication Date
DK3820856T3 true DK3820856T3 (da) 2022-10-24

Family

ID=67957191

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19769220.5T DK3820856T3 (da) 2018-07-10 2019-07-08 C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner

Country Status (27)

Country Link
US (3) US11111262B2 (da)
EP (1) EP3820856B9 (da)
JP (2) JP7309862B2 (da)
KR (1) KR20210031682A (da)
CN (1) CN112334455B (da)
AU (1) AU2019301946B2 (da)
BR (1) BR112021000370A2 (da)
CA (1) CA3105940A1 (da)
CL (1) CL2021000033A1 (da)
CY (1) CY1125704T1 (da)
DK (1) DK3820856T3 (da)
ES (1) ES2928634T3 (da)
HR (1) HRP20221381T1 (da)
HU (1) HUE060140T2 (da)
IL (1) IL279993B2 (da)
LT (1) LT3820856T (da)
MX (1) MX2021000340A (da)
MY (1) MY201687A (da)
PH (1) PH12020551905A1 (da)
PL (1) PL3820856T3 (da)
PT (1) PT3820856T (da)
RS (1) RS63712B1 (da)
SG (1) SG11202011066XA (da)
SM (1) SMT202200435T1 (da)
TW (1) TWI821328B (da)
UY (1) UY38293A (da)
WO (1) WO2020012336A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269822B2 (en) 2018-07-09 2025-04-08 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
RS63712B1 (sr) * 2018-07-10 2022-11-30 Glaxosmithkline Ip Dev Ltd Jedinjenja c-manozida korisna za tretman infekcija urinarnog trakta
MX2021011302A (es) 2019-03-19 2022-01-19 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos.
CA3138394A1 (en) 2019-05-07 2020-11-12 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
KR20230028268A (ko) 2020-05-29 2023-02-28 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 헤테로시클릭 화합물
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics
WO2026077990A1 (en) 2024-10-09 2026-04-16 Glaxosmithkline Intellectual Property Development Limited Novel use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
AU704114B2 (en) 1993-11-18 1999-04-15 Siga Technologies, Inc. Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
DE60006390T2 (de) 1999-06-28 2004-05-13 Lear Corp., Southfield Verfahren zum formen eines blasgeformten kunststoffteils mit filmscharnier
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2001095876A1 (en) 2000-06-09 2001-12-20 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
EP1679299A1 (en) 2003-10-08 2006-07-12 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
NZ616764A (en) 2009-12-14 2014-11-28 Univ Basel Mannose derivatives as antagonists of bacterial adhesion
EP2672820B1 (en) 2011-02-07 2019-04-17 The Washington University Mannoside compounds and methods of use thereof
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
WO2013134415A1 (en) 2012-03-07 2013-09-12 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP2690105A1 (en) 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
US20150197536A1 (en) 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
WO2014055474A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP3388441A1 (en) 2012-12-18 2018-10-17 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
MX2015012472A (es) 2013-03-12 2016-02-10 Vertex Pharma Derivados de manosa para el tratamiento de infecciones bacterianas.
CN105682665A (zh) * 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
WO2017021549A1 (en) 2015-08-05 2017-02-09 Enterome Mannose derivatives useful for treating pathologies associated with adherent e. coli
JP2019508504A (ja) * 2016-03-11 2019-03-28 フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疾病の処置に有用なｃ−グリコシド化合物
AU2017238392A1 (en) 2016-03-23 2018-09-27 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of FimH useful for treating disease
WO2019076931A1 (en) 2017-10-16 2019-04-25 Enterome NEW TOOLS FOR EVALUATING THE THERAPEUTIC EFFECTIVENESS OF FIMH BLOCKERS
RS63712B1 (sr) 2018-07-10 2022-11-30 Glaxosmithkline Ip Dev Ltd Jedinjenja c-manozida korisna za tretman infekcija urinarnog trakta
CN109818150A (zh) 2019-03-12 2019-05-28 信利半导体有限公司 一种液晶天线及其制作方法

Also Published As

Publication number Publication date
BR112021000370A2 (pt) 2021-04-06
US20230287028A1 (en) 2023-09-14
CY1125704T1 (el) 2026-02-25
TW202019893A (zh) 2020-06-01
PH12020551905A1 (en) 2021-06-21
JP2022191325A (ja) 2022-12-27
IL279993A (en) 2021-03-01
US20210395287A1 (en) 2021-12-23
US20210017212A1 (en) 2021-01-21
KR20210031682A (ko) 2021-03-22
US11697665B2 (en) 2023-07-11
PL3820856T3 (pl) 2022-12-19
TWI821328B (zh) 2023-11-11
AU2019301946A1 (en) 2020-11-26
EP3820856B1 (en) 2022-08-31
HUE060140T2 (hu) 2023-02-28
LT3820856T (lt) 2022-11-10
IL279993B1 (en) 2023-09-01
UY38293A (es) 2020-05-29
WO2020012336A1 (en) 2020-01-16
US11111262B2 (en) 2021-09-07
CN112334455B (zh) 2022-07-01
AU2019301946B2 (en) 2022-03-31
CL2021000033A1 (es) 2021-07-30
HRP20221381T1 (hr) 2023-01-06
EP3820856B9 (en) 2023-07-12
EP3820856A1 (en) 2021-05-19
MX2021000340A (es) 2021-03-25
PT3820856T (pt) 2022-10-17
JP2022511594A (ja) 2022-02-01
RS63712B1 (sr) 2022-11-30
JP7483820B2 (ja) 2024-05-15
JP7309862B2 (ja) 2023-07-18
CN112334455A (zh) 2021-02-05
ES2928634T3 (es) 2022-11-21
IL279993B2 (en) 2024-01-01
MY201687A (en) 2024-03-13
US12552824B2 (en) 2026-02-17
SMT202200435T1 (it) 2023-01-13
SG11202011066XA (en) 2021-01-28
CA3105940A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
DK3820856T3 (da) C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner
DK3710446T3 (da) Forbindelser, der kan anvendes til at hæmme CDK7
DK3501542T3 (da) Esketamin til behandling af depression
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3612215T3 (da) Sammensætninger til behandling af lungeinflammation
DK3019503T3 (da) Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
DK3019499T3 (da) Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK2988743T3 (da) Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
DK4154882T3 (da) Behandling af amyotrofisk lateralsklerose med pridopidin
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3511328T3 (da) Organiske monobactam-forbindelser til behandling af bakterieinfektioner
EP3259009C0 (en) Improved urinary catheter
LT4356969T (lt) Kondensuoti tricikliniai piridazinono junginiai, naudotini ortomiksovirusinių infekcijų gydymui
DK3524255T3 (da) Sammensætning til behandling af acne
DK3297654T3 (da) Behandling af post-bariatrisk hypoglykæmi med exendin(9-39)
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
IL282311A (en) Use of reboxetine to treat narcolepsy
DK3307267T3 (da) Behandling af multipel sklerose
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3340993T3 (da) Forbindelse til anvendelse i fremgangsmåder til behandling af polycystisk nyresygdom
DK3377064T3 (da) Orvepitant til behandling af kronisk hoste
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi